1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,250 | 6,450 | 13:05 | |
| 6,200 | 6,400 | 24.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | HENLIUS (02696): GRANTS OF OPTIONS AND RSUS | 1 | HKEx | ||
| 16.07. | HENLIUS HLX18 Completes First Patient Dosing in Mainland China Clinical Trial | 1 | AASTOCKS | ||
| 16.07. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE GLOBAL FIRST PATIENT HAS BEEN DOSED IN AN INTERNATIONAL MULTI-CENTER PHASE 1 CLINICAL STUDY OF NIVOLUMAB ... | 1 | HKEx | ||
| SHANGHAI HENLIUS BIOTECH Aktie jetzt für 0€ handeln | |||||
| 10.07. | HENLIUS IND Application for Phase 1 Clinical Trial of HLX37 Combined With HLX43 for Solid Tumor Treatment Approved by NMPA | 4 | AASTOCKS | ||
| 10.07. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE PHASE 1 CLINICAL TRIAL OF HLX37 (RECOMBINANT HUMANISED ANTI-PD-L1 ... | 1 | HKEx | ||
| 08.07. | HENLIUS HLX05-N Administers First Patient in Phase I Clinical Study for mCRC | 1 | AASTOCKS | ||
| 08.07. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF CETUXIMAB INJECTION BIOSIMILAR HLX05-N (RECOMBINANT ... | - | HKEx | ||
| 30.06. | HENLIUS Says Phase I Clinical Study of HLX48 for Injection for Solid Tumor Treatment Completes First Patient Dosing in China | 1 | AASTOCKS | ||
| 30.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX48 FOR INJECTION (AN ANTIBODY-DRUG CONJUGATE ... | 1 | HKEx | ||
| 26.06. | HENLIUS HLX13 for First-line Treatment of Unresectable Advanced Hepatocellular Carcinoma Completes First US Patient Dosing in Phase I Trial | 3 | AASTOCKS | ||
| 25.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT IN THE UNITED STATES HAS BEEN DOSED IN AN INTERNATIONAL MULTICENTER PHASE 1 CLINICAL STUDY ... | 1 | HKEx | ||
| 25.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE EUROPEAN COMMISSION (EC) HAS APPROVED A NEW INDICATION FOR SERPLULIMAB INJECTION (TRADE NAME IN CHINESE ... | - | HKEx | ||
| 23.06. | Organon and Henlius launch Prolia and Xgeva biosimilars in Canada | 2 | Seeking Alpha | ||
| 17.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL TRIAL OF HLX3902 INJECTION (STEAP1XCD3XCD28 TRISPECIFIC ANTIBODY) FOR THE TREATMENT OF ... | 1 | HKEx | ||
| 17.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - HANBEIYOU (PERTUZUMAB INJECTION) PASSING GMP COMPLIANCE INSPECTION | - | HKEx | ||
| 16.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - THE PHASE 2 CLINICAL TRIAL OF HLX43 FOR INJECTION (AN ANTI-PD-L1 ANTIBODY-DRUG CONJUGATE) IN COMBINATION WITH ... | - | HKEx | ||
| 16.06. | HENLIUS (02696): VOLUNTARY ANNOUNCEMENT - AN INTERNATIONAL MULTI-CENTER PHASE 3 CLINICAL STUDY OF RECOMBINANT ANTI-VEGF HUMANISED MONOCLONAL ANTIBODY ... | - | HKEx | ||
| 11.06. | HENLIUS (02696): NEXT DAY DISCLOSURE RETURNS | 3 | HKEx | ||
| 09.06. | HENLIUS (02696): INSIDE INFORMATION ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) FOR NEW INDICATION OF HANSIZHUANG (SERPLULIMAB INJECTION) IN COMBINATION ... | 1 | HKEx | ||
| 08.06. | Alligator Bioscience Comments on Henlius Update on Global Phase 3 Trial with HLX22 | 379 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 8, 2026 / Alligator Bioscience (STO:ATORX) today comments on a recent update regarding patient recruitment in the ongoing Phase 3 clinical trial of HLX22, developed... ► Artikel lesen |
1 2 3 4 5 Weiter >>
91 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,335 | -0,66 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,680 | +0,15 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| TARSUS PHARMACEUTICALS | 58,66 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| PRAXIS PRECISION MEDICINES | 324,95 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,430 | -0,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,26 | -0,01 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| DISC MEDICINE | 74,12 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,95 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,740 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 19,110 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,690 | 0,00 % | Vir Biotechnology: Abgang des Finanzchefs schickt Aktie auf Talfahrt | ||
| TANGO THERAPEUTICS | 26,630 | 0,00 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| EDGEWISE THERAPEUTICS | 40,790 | -0,12 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 45,700 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 21,860 | +0,97 % | Scribe Therapeutics Inc.: Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering | ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR... ► Artikel lesen |
Das Unternehmen SHANGHAI HENLIUS BIOTECH INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,200 Euro und damit -3,12 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI HENLIUS BIOTECH INC finden Sie auf Wallstreet Online.